MR texture analysis: potential imaging biomarker for predicting the chemotherapeutic response of patients with colorectal liver metastases

[1]  Sang Joon Park,et al.  Prediction of the therapeutic response after FOLFOX and FOLFIRI treatment for patients with liver metastasis from colorectal cancer using computerized CT texture analysis. , 2016, European journal of radiology.

[2]  Dakai Zhang,et al.  Use of texture analysis based on contrast‐enhanced MRI to predict treatment response to chemoradiotherapy in nasopharyngeal carcinoma , 2016, Journal of magnetic resonance imaging : JMRI.

[3]  M. Zeng,et al.  Potential of MR histogram analyses for prediction of response to chemotherapy in patients with colorectal hepatic metastases , 2016, European Radiology.

[4]  B. Ganeshan,et al.  Performance of diffusion-weighted imaging, perfusion imaging, and texture analysis in predicting tumoral response to neoadjuvant chemoradiotherapy in rectal cancer patients studied with 3T MR: initial experience , 2016, Abdominal Radiology.

[5]  Walter H Backes,et al.  CT texture analysis in colorectal liver metastases: A better way than size and volume measurements to assess response to chemotherapy? , 2016, United European gastroenterology journal.

[6]  Wen Yan,et al.  Effective staging of fibrosis by the selected texture features of liver: Which one is better, CT or MR imaging? , 2015, Comput. Medical Imaging Graph..

[7]  N. Michoux,et al.  Texture analysis on MR images helps predicting non-response to NAC in breast cancer , 2015, BMC Cancer.

[8]  Alejandro Munoz del Rio,et al.  CT textural analysis of hepatic metastatic colorectal cancer: pre-treatment tumor heterogeneity correlates with pathology and clinical outcomes , 2015, Abdominal Imaging.

[9]  Felix G. Meinel,et al.  Texture Analysis as Imaging Biomarker of Tumoral Response to Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients Studied with 3-T Magnetic Resonance , 2015, Investigative radiology.

[10]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[11]  Jungsu S. Oh,et al.  Intratumor Textural Heterogeneity on Pretreatment 18F-FDG PET Images Predicts Response and Survival After Chemoradiotherapy for Hypopharyngeal Cancer , 2015, Annals of Surgical Oncology.

[12]  Michael E. Egger,et al.  Assessment of chemotherapy response in colorectal liver metastases in patients undergoing hepatic resection and the correlation to pathologic residual viable tumor. , 2013, Journal of the American College of Surgeons.

[13]  Vicky Goh,et al.  Assessment of tumor heterogeneity by CT texture analysis: can the largest cross-sectional area be used as an alternative to whole tumor analysis? , 2013, European journal of radiology.

[14]  Vicky Goh,et al.  Are Pretreatment 18F-FDG PET Tumor Textural Features in Non–Small Cell Lung Cancer Associated with Response and Survival After Chemoradiotherapy? , 2013, The Journal of Nuclear Medicine.

[15]  J. Shindoh,et al.  Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  Myeong-Jin Kim,et al.  Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria. , 2012, AJR. American journal of roentgenology.

[17]  K. Miles,et al.  Tumour heterogeneity in non-small cell lung carcinoma assessed by CT texture analysis: a potential marker of survival , 2012, European Radiology.

[18]  N. Thacker,et al.  Quantifying heterogeneity in human tumours using MRI and PET. , 2012, European journal of cancer.

[19]  S. Curley,et al.  Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. , 2009, JAMA.

[20]  Balaji Ganeshan,et al.  Colorectal cancer: texture analysis of portal phase hepatic CT images as a potential marker of survival. , 2009, Radiology.

[21]  L. Shen,et al.  Apparent diffusion coefficient: potential imaging biomarker for prediction and early detection of response to chemotherapy in hepatic metastases. , 2008, Radiology.

[22]  N. Kemeny.  Management of liver metastases from colorectal cancer. , 2006, Oncology.

[23]  G. Launoy,et al.  A population‐based study of the incidence, management and prognosis of hepatic metastases from colorectal cancer , 2006, The British journal of surgery.

[24]  M. Valerio,et al.  Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  J. Hecht,et al.  Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  C. Tournigand,et al.  FOLFIRI Followed by FOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer: A Randomized GERCOR Study , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  V. Goh,et al.  Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. , 2013, Radiology.

[28]  V. Goh,et al.  Non-small cell lung cancer: histopathologic correlates for texture parameters at CT. , 2013, Radiology.

[29]  A. Jemal,et al.  Global Cancer Statistics , 2011 .